Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Vyne Therapeutics Inc (VYNE)
:VYNE
VYNE Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.57 - $4.30
Previous CloseN/A
Volume117.27K
Average Volume (3M)101.63K
Market Cap
$39.83M
Enterprise Value$9.95M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.70
Next Earnings
Feb 27, 2025EPS Estimate
-0.3Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.85
Shares Outstanding14,751,433
10 Day Avg. Volume76,492
30 Day Avg. Volume101,634
Standard Deviation0.25
R-Squared0.07
Alpha-0.07
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)80.79
Price to Cash Flow (P/CF)-1.20
P/FCF Ratio0.00
Enterprise Value/Market Cap0.25
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit23.48
Enterprise Value/Ebitda-0.27
Forecast
1Y Price Target
$6.19Price Target Upside125.91% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
---
VYNE Therapeutics News
See All VYNE News
---
Bulls Say, Bears Say
Bulls Say
Clinical TrialsVYN202 recently demonstrated an encouraging PK/PD and safety profile in a Phase 1a MAD trial.
Market PotentialVYNE is pioneering the development of BET inhibitors in large I&I opportunities, with a focus on non-segmental vitiligo, a market with high growth potential.
Bears Say
Market CompetitionPsoriasis is a relatively mature market and looks like a well-suited steppingstone for VYN202 to demonstrate clinical PoC.
---
Ownership Overview
11.35% Insiders
5.57% Mutual Funds
31.85% Other Institutional Investors
47.78% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
VYNE FAQ
What was Vyne Therapeutics Inc’s price range in the past 12 months?
Vyne Therapeutics Inc lowest stock price was $1.57 and its highest was $4.30 in the past 12 months.
What is Vyne Therapeutics Inc’s market cap?
Vyne Therapeutics Inc’s market cap is $39.83M.
When is Vyne Therapeutics Inc’s upcoming earnings report date?
Vyne Therapeutics Inc’s upcoming earnings report date is Feb 27, 2025 which is in 4 days.
How were Vyne Therapeutics Inc’s earnings last quarter?
Vyne Therapeutics Inc released its earnings results on Nov 07, 2024. The company reported -$0.29 earnings per share for the quarter, missing the consensus estimate of -$0.235 by -$0.055.
Is Vyne Therapeutics Inc overvalued?
According to Wall Street analysts Vyne Therapeutics Inc’s price is currently Undervalued.
Does Vyne Therapeutics Inc pay dividends?
Vyne Therapeutics Inc does not currently pay dividends.
What is Vyne Therapeutics Inc’s EPS estimate?
Vyne Therapeutics Inc’s EPS estimate is -0.3.
How many shares outstanding does Vyne Therapeutics Inc have?
Vyne Therapeutics Inc has 14,751,433 shares outstanding.
What happened to Vyne Therapeutics Inc’s price movement after its last earnings report?
Vyne Therapeutics Inc reported an EPS of -$0.29 in its last earnings report, missing expectations of -$0.235. Following the earnings report the stock price went up 0.958%.
Which hedge fund is a major shareholder of Vyne Therapeutics Inc?
Currently, no hedge funds are holding shares in VYNE
---
VYNE Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$6.19 (125.91% Upside)
$6.19 (125.91% Upside)
Insider Transactions
Bought Shares
Worth $43.8K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▲ 0.9%
Last 30 Days ▲ 1.5%
Last 30 Days ▲ 1.5%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
26.26%
12-Months-Change
Fundamentals
Return on Equity
-90.47%
Trailing 12-Months
Asset Growth
295.48%
Trailing 12-Months
Company Description
Vyne Therapeutics Inc
Menlo Therapeutics Inc. operates as biopharmaceutical company which is focused on the development and commercialization of serlopitant for the treatment of pruritus, or itch, associated with dermatologic conditions such as atopic dermatitis, psoriasis and prurigo nodularis. The company was founded in October, 2011 and is headquartered in Redwood City, CA.
---
VYNE Stock 12 Month Forecast
Average Price Target
$6.19
▲(125.91% Upside)
Technical Analysis
ACADIA Pharmaceuticals
―
Cidara Therapeutics
―
Blueprint Medicines
―
Aclaris Therapeutics
―
Journey Medical Corp
―
Best Analysts Covering VYNE
1 Year
1 Year Success Rate
5/9 ratings generated profit
1 Year Average Return
+3.84%
reiterated a buy rating 2 months ago
Copying Rami Katkhuda's trades and holding each position for 1 Year would result in 55.56% of your transactions generating a profit, with an average return of +3.84% per trade.
---